Now FDA ClearedTandem Mobi Tubeless
World’s first and only tubeless AID system with up to 7 days of wear1*
Tandem Diabetes Care automated insulin delivery (AID) systems are powered by Control-IQ+, the only system with AutoBolus, which helps maximize outcomes and can be optimized for even more patient needs.2
Tested
Tandem AID systems have been peer-reviewed in more than 115 manuscripts. There are more than 440,000 Tandem AID users worldwide with more than 300 million patient days.1
Trusted
Immediate and sustained improvements across patient populations with significantly fewer adverse events.3 Only Control-IQ+ has AutoBolus to help reduce user burden.
Flexible
Expanded weight and age indications for very small and very large insulin requirements with unique, optional features to quickly adjust for lifestyle and fluctuating insulin needs.
Better Management for Type 2 Diabetes
Control-IQ+ is the only automated insulin delivery (AID) system with a randomized controlled clinical trial4 studying adults with type 2 diabetes that outperforms standard insulin therapies† with a CGM.‡
Why Control-IQ+
Immediate & Sustained Improvements3
Control-IQ+ has no learning time. Improvements were seen within the first 24 hours and the results were sustained during the following 13 weeks. It predicts, calculates, and automatically adjusts insulin to achieve better glucose control.
AutoBolus Helps Reduce Patient Burden
If sensor glucose is predicted to be above 180 mg/dL, Control-IQ+ technology may automatically deliver an AutoBolus — which is proactively delivered before glucose elevates — to help prevent hyperglycemia.§
Solutions For Individual Patient Needs
Tandem Diabetes Care offers two unique AID systems, both powered by Control-IQ+ technology, which give your patients the options they need to best fit their lifestyle.
Tandem Mobi System
This insulin pump can be worn almost anywhere,^ giving patients more options for how they manage their diabetes. It’s also fully controllable by a personal, compatible smartphone** with the ability to bolus from the pump if the mobile app is not available.
t:slim X2 Insulin Pump
This user-friendly, all-in-one system is sleek, modern, and has an easy-to-use color touchscreen. It pairs with multiple CGM sensors and patients can bolus from their compatible smartphone.††
Tandem SourceReporting Made Simple
Tandem Source is a platform for healthcare professionals to see important diabetes therapy data, access reports, and find the tools to help patients manage their diabetes.
Provider Resources
Explore educational resources and product tips so your patients can make the most of their experience.
Clinical Evidence
Clinical studies have demonstrated the safety, efficacy, and ease of use of Tandem automated insulin delivery.
Industry Events
Browse live conferences, virtual events, and learning environments attended or hosted by Tandem.
Learn More Today!
Sign up to receive the latest Tandem news and educational resources.
* Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use.
† Standard Insulin Therapies = Multiple daily injections or sensor augmented pump.
‡ CGM sold separately.
§ If glucose values are predicted to be above 180 mg/dL, Control-IQ+ technology calculates an AutoBolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.
^ Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin.
** The mobile app requires a compatible smartphone model and operating system (sold separately).
†† Bolus delivery from the Tandem t:slim mobile app requires a compatible smartphone model and operating system, an app update, a remote software update on the t:slim X2 insulin pump, and additional training.
References
Note: Some studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 CGM sensor.
1. As of Nov., 2026. Data on file, Tandem Diabetes Care.
2. Messer LH, Breton M. Diabetes Technol Ther. 2023;25(12):877-882.
3. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342.
4. Kudva YC, et al. N Engl J Med. 2025;392(18):1801-1812. doi: 10.1056/NEJMoa2415948
Important Safety Information
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 2 years of age and greater.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology is intended for use with compatible interoperable continuous glucose monitors (iCGM), alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is not a substitute for your own active diabetes management.
Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater. Control-IQ+ technology is intended for use in pregnancy complicated by Type 1 diabetes mellitus, provided the linked CGM system is suitable for use in pregnancy.
WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old. Control-IQ+ technology should also not be used in patients who require less than a total daily insulin dose of 5 units per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed in order for Control-IQ+ technology to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
Tandem t:slim mobile app: The feature set available within the Tandem t:slim mobile app is dependent on the pump software version and the compatible smartphone’s model and operating system (OS).
The Display and Data Upload feature set provides a secondary display of pump and continuous glucose monitoring (CGM) information, including display of your pump alerts and alarms, and enables wireless uploading of pump and CGM data to the Tandem cloud through an internet or wireless data connection. Standard carrier data rates may apply.
The Bolus Delivery plus Display and Data Upload feature set additionally allows users to request, stop, and cancel a bolus on the pump from the Tandem t:slim mobile app. At least one smartphone security setting must be enabled to utilize the Bolus Delivery feature of the Tandem t:slim mobile app.
WARNING: Always rely on your pump to make therapy decisions when using a smartphone that is incompatible with the Bolus Delivery feature.
PRECAUTIONS: Always rely on your pump to make therapy decisions if using a smartphone that is incompatible, the smartphone is lost or damaged, or the smartphone loses Bluetooth® connectivity with your pump. Important pump alerts and alarms are only received as app notifications when enabled and the app is either active or running in the background.
The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.